Methods include the use of TLR agonists, IFN-γ and CSF1R inhibitors, etc. (55–59), which promote the production of pro-inflammatory cytokines and anti-tumor factors by altering the polarization state of macrophages to enhance the overall anti-tumor immune response. The gene discussed is CSF1R; the disease is neoplasm.